Mitoxantrone as Second-Line Single Agent in Metastatic Breast Cancer
作者:
Moshe Stein,
Riva Borovik,
Eliezer Robinson,
期刊:
Oncology
(Karger Available online 1991)
卷期:
Volume 48,
issue 4
页码: 265-269
ISSN:0030-2414
年代: 1991
DOI:10.1159/000226940
出版商: S. Karger AG
关键词: Metastatic breast cancer;Second-line treatment;Response;Cardiotoxicity
数据来源: Karger
摘要:
Mitoxantrone (MIX), a member of the anthraquinone chemical class, was found to be a potential anticancer agent. It has a similar spectrum of activity as Adriamycin in experimental and human tumors. Thirty-five female patients with metastatic breast cancer, refractory to previous chemotherapy, were treated between 1986 and 1987 with MIX (14 mg/m2 i.v. every 3 weeks); patients with diffuse bone metastases or heavily pretreated patients received 10–12 mg/m2 MIX. All patients were evaluable for response and toxicity. Two patients achieved complete response and 4 partial response, giving an overall response rate of 17%. Median time of response was 5.5 months. The drug was well tolerated. Objective response was obtained mostly in patients with a performance status (Karnofsky scale) of more than 70%, and in those who received more than 12 mg/m2 MIX per course. One patient developed cardiomyopathy, another an acute myocardial infarction, and 3 patients had pathological changes on echocardiography or multigated nuclear angiography. Hematological and gastrointestinal toxicity was tolerable. We found MIX to be a potentially effective second-line treatment with mild toxicity in patients with metastatic breast cance
点击下载:
PDF
(2348KB)
返 回